Exploring Lecanemab: Mechanisms, Efficacy, and Clinical Implications in Alzheimer's Disease Management

Ziming He

doi:10.62051/zw3jap74

Authors

Ziming He

DOI:

https://doi.org/10.62051/zw3jap74

Keywords:

Alzheimer's disease; lecanemab; clinical progress.

Abstract

Lecanemab, with accelerated approval from the FDA, becomes a notable and promising drug to fight against Alzheimer's disease (AD). As one monoclonal antibody, it is reported that lecanemab can reduce cognitive decline caused by AD by reducing amyloid-beta in patients. However, some concerns, uncertainties and limitations of Lecanemab in clinical trials have also been brought out. This study analyses the existing methods to cure AD and researches in clinical phases of lecanemab and relevant detailed information. This article aims to provide a relevant view of key aspects of lecanemab’s performance, including its mechanisms, effects, safety, limitations and tips. Thus, this study shows an updated summary for those who want to be exposed to the current situations of applications of Lecanemab. The nature of AD remains complex to us nowadays, so further fundamental research concerning the causes and mechanisms of AD. For those drugs targeting AD, many aspects involving itself and its usage still need to be investigated.

Downloads

Download data is not yet available.

References

[1] Wright AC, Lin GA, Whittington MD, Agboola F, Herron-Smith S, Rind DM, Pearson SD. The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum. J Manag Care Spec Pharm, 2023, 29(9): 1078-1083.

[2] Abdelazim K, Allam AA, Aff B, Abdulazeem H, Elbehiry AI. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer’s disease: A systematic review and meta-analysis of randomized controlled trials. Neurological Sciences, 2024, 45: 3583–3597.

[3] Neat M, Covaliu A, Ionit I, Jugurt A, Davidescu EI, Popescu BO. Monoclonal Antibody Therapy in Alzheimer’s Disease. Pharmaceutics, 2024, 16(1): 60.

[4] Hossain MF, Husna AU, Kharel M. Use of lecanemab for the treatment of Alzheimer’s disease: A systematic review. Brain and Behavior, 2024, 14: e3592.

[5] Abdelazim K, Allam AA, Aff B, Abdulazeem H, Elbehiry AI. The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer’s disease: A systematic review and meta-analysis of randomized controlled trials. Neurological Sciences, 2024, 45(10): 3583–3597.

[6] Doroszkiewicz J, Mroczko B. New possibilities in the therapeutic approach to Alzheimer’s disease. International Journal of Molecular Sciences, 2022, 23(16): 8902.

[7] Zhong CCW, Zhao J, Wong CHL, Wu IXY, Mao C, Yeung JWF, Chung VCH. Methodological quality of systematic reviews on treatments for Alzheimer’s disease: A cross-sectional study. Alzheimer’s Research & Therapy, 2022, 14: 159.

[8] Zhang J. Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment. Inflammation Research, 2023, 72(9): 1873-1876.

[9] Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer’s disease: a systematic review and meta-analysis of randomized clinical trials. Frontiers in Aging Neuroscience, 2023, 15: 1169499.

[10] Wright AC, Lin GA, Whittington MD, Agboola F, Herron-Smith S, Rind D, Pearson SD. The effectiveness and value of lecanemab for early Alzheimer disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum. Journal of Managed Care & Specialty Pharmacy, 2023, 29(9): 1078-1083.

[11] Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: Appropriate Use Recommendations. The Journal of Prevention of Alzheimer’s Disease, 2023, 10(3): 362-377.